Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse

PHASE3RecruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Polymyalgia Rheumatica

Interventions

DRUG

Rituximab

1000mg rituximab in 250ml NaCl 0.9% intravenously

DRUG

Placebo

Placebo in 250ml NaCl 0.9% intravenously

Trial Locations (1)

RECRUITING

Sint Maartensklineik, Ubbergen

All Listed Sponsors

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Dutch Arthritis Association

INDUSTRY

lead

Sint Maartenskliniek

OTHER